Program
Charcoal
Also written as “AST-120”, “charcoal” and “Z7200 with oral activated charcoal”.
Its studies are mostly in Multiple Sclerosis · Renal Insufficiency, Chronic · Asthma · Pouchitis · Hepatic Encephalopathy, led by 2 companies.
Drug pageCharcoal: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeuticsits history only | 70 open or running | phase 3since May 1, 2006 | May 1, 2006 | none ahead |
| Zambon SpA | 20 open or running | phase 1since Sep 2, 2014 | Sep 2, 2014 | none ahead |
Also a collaborator on its studies: Kureha, Kyntra Bio and Toray Industries.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Zambon SpA only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 2, 2014First study: phase 1 study in AsthmaFirst studyNCT02237508 · 90 enrolled · United Kingdom
- Dec 14, 2015Phase 1 study in AsthmaNCT02631941 · 91 enrolled · United Kingdom
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 Zambon SpA leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02631941Asthma · United Kingdom | 1 | Completed | Jul 2016 | 91 |
| NCT02237508Asthma · United Kingdom | 1 | Completed | Feb 2015 | 90 |
How it is read
Names in the registry
- “AST-120”, 10 entries
- “charcoal”, 2 entries
- “Z7200 with oral activated charcoal”, 2 entries
- “Symbicort Turbohaler with oral activated charcoal”, 1 entry
- “Activated Charcoal”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 2 studies
- Renal Insufficiency, Chronic, 2 studies
- Asthma, 2 studies
- Pouchitis, 2 studies
- Hepatic Encephalopathy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.